Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
Authors' conclusion
Patient's and parents' preferences were the strongest driver of a decision to postpone biologic therapy withdrawal in children with clinically inactive non-systemic JIA and prolongs treatment duration.
Study context
- Population
- Pediatric rheumatologists in Canada and the Netherlands; vignettes of children with clinically inactive non-systemic JIA40% response rate of 83
- Participants
- 33 participants
- Outcome
- Whether pediatric rheumatologists would withdraw biologic therapy at their minimum treatment time, and if not, how long they would continue it
Methodological detailssurvey, patient vignettes, logistic and interval regression analysis
- Survey
- Patient vignettes
- Logistic and interval regression analysis
Main finding
As reported in the abstract
Factors associated with postponing biologic therapy withdrawal
Child and/or parents prefer continuation, OR
6.3
p < 0.001
Flare in current treatment period, OR
3.9
p = 0.001
Uveitis in current treatment period, OR
3.9
p < 0.001
Withdrawal initiated later on average when child or parent prefer to continue (months)
6.7
Observational data: associations, not effects.
Original publication
Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists? Pediatr Rheumatol Online J. Published 11 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →